General Dermatology
Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Anti-Aging
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management

Utilizing the Psoriasis Toolbox

August 5, 2021

Linda Stocum, Associate Editor

Video

In this video interview, Jerry Bagel, MD, MS, discusses improvement in quality of life for pediatric psoriasis patients and current and emerging treatments.

Jerry Bagel, MD, MS, director of the Psoriasis Treatment Center of New Jersey & Eczema Treatment Center of New Jersey in East Windsor, and a member of the National Psoriasis Foundation (NPF) board of directors

Related Videos

Related Content

Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis

Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Apremilast Demonstrates Consistent Safety and Efficacy in Children with Moderate to Severe Plaque Psoriasis at 52 Weeks

Apremilast Demonstrates Consistent Safety and Efficacy in Children with Moderate to Severe Plaque Psoriasis at 52 Weeks

Topical Melatonin and Rosuvastatin Reduce Severity of Mild to Moderate Plaque Psoriasis

Topical Melatonin and Rosuvastatin Reduce Severity of Mild to Moderate Plaque Psoriasis

Related Content

Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis

Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Apremilast Demonstrates Consistent Safety and Efficacy in Children with Moderate to Severe Plaque Psoriasis at 52 Weeks

Apremilast Demonstrates Consistent Safety and Efficacy in Children with Moderate to Severe Plaque Psoriasis at 52 Weeks

Topical Melatonin and Rosuvastatin Reduce Severity of Mild to Moderate Plaque Psoriasis

Topical Melatonin and Rosuvastatin Reduce Severity of Mild to Moderate Plaque Psoriasis

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.